mAbxience | News
5th Castilla y León’s Best Director Awards
04/30/2018
On the occasion of the awards granted by Castilla y León Económica magazine for the fifth year, Luisa Amoedo, director of mAbxience León, has been awarded as Best Export / Internationalization Director. The jury of the 5th Castilla y León’s Best Director Awards is composed of José María Ribot García, General Manager of Instituto para […]
Cancer Chemotherapy and Pharmacology has published comparative data of rituximab biosimilar RTXM83R in lymphoma patients
03/06/2018
The journnal Cancer Chemotherapy and Pharmacology has recently published the randomized, double-blind, phase III and comparative clinical study of pharmacokinetics and pharmacodynamics between RTXM83™ rituximab biosimilar and its reference product in diffuse large B-cell lymphoma patients. The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax). To demonstrate biosimilarity […]
2nd National Conference on Biosimilars
03/05/2018
mAbxience actively participated in the 2nd National Conference on Biosimilars organised by the Spanish Biosimilar Medicines Association, BioSim. The conference, entitled “Biosimilars: evidence and efficiency”, took place at the Ministry of Health, Social Services and Equality in Madrid on 21st February. Francisco Olivera, Operations Manager at mAbxience León, shared the “Evidence: from R&D to authorisation” […]